Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toludesvenlafaxine withdrawal trial in depression
NCT06426485Phase 4Not yet recruiting
- Sponsor
- Luye Pharma Group
- Start
- May 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of toludesvenlafaxine in major depressive disorder (MDD), sponsored by Luye Pharma Group. Planned start May 2024; status: not yet recruiting.
02
Drugs
toludesvenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06426485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426485.